Prestige Consumer director granted 2,981 RSUs

Prestige Consumer Healthcare Inc. reported that director Celeste A. Clark acquired an equity award of 2,981 restricted stock units, valued at $155,000 based on a $52.00 closing share price on August 4, 2026, under the director compensation program.

Rhea-AI Filing Summary

Prestige Consumer Healthcare Inc. reported that director Celeste A. Clark acquired an equity award of 2,981 restricted stock units, valued at $155,000 based on a $52.00 closing share price on August 4, 2026, under the director compensation program. The units vest on the first anniversary of grant and will be settled in one share of common stock per vested unit upon the earliest of Clark’s death, separation, or a change in control. Following this award, 16,511 shares of common stock are reported as directly owned.

Insider Trade Summary

Grant/Award: 2,981 shares

Grant/Award 1 txn

Insider Clark Celeste A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, par value $0.01 per share F1	2,981	$0.00	$0.00

Holdings After Transaction: Common Stock, par value $0.01 per share — 16,511 shares (Direct)

Footnotes (1)

1. F1. The Reporting Person received 2,981 restricted stock units equal to $155,000 divided by the closing stock price of $52.00 on August 4, 2026, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control.

Key Figures

RSU grant size: 2,981 units Grant value: $155,000 Closing stock price: $52.00 per share +1 more

4 metrics

RSU grant size 2,981 units Restricted stock units granted to director on August 4, 2026

Grant value $155,000 Value used to calculate number of restricted stock units

Closing stock price $52.00 per share Closing share price on August 4, 2026 used in RSU calculation

Shares owned after grant 16,511 shares Total common shares reported as directly owned following the transaction

Key Terms

restricted stock units, director compensation program, change in control

3 terms

restricted stock units financial

"received 2,981 restricted stock units equal to $155,000 divided by the closing"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

director compensation program financial

"on August 4, 2026, in connection with the Issuer's director compensation program"

change in control regulatory

"promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Prestige Consumer Healthcare (PBH) report for Celeste A. Clark?

Prestige Consumer Healthcare reported that director Celeste A. Clark received 2,981 restricted stock units as part of its director compensation program. The equity award is valued at $155,000, based on a $52.00 closing stock price on August 4, 2026, and vests after one year.

How was the size of Celeste A. Clark’s PBH equity award determined?

The award size was calculated by dividing $155,000 by Prestige Consumer Healthcare’s $52.00 closing stock price on August 4, 2026, resulting in 2,981 restricted stock units. This ties the director’s compensation value directly to the company’s share price on the grant date.

When do Celeste A. Clark’s PBH restricted stock units vest and settle?

The 2,981 restricted stock units granted to Celeste A. Clark vest on the first anniversary of the grant date. They will be settled in one share of common stock per vested unit shortly after the earliest of her death, separation from service, or a change in control.

How many PBH shares does Celeste A. Clark hold after this equity grant?

After the reported transaction, Celeste A. Clark is shown as directly owning 16,511 shares of common stock of Prestige Consumer Healthcare. This figure reflects her total directly held position immediately following the grant of 2,981 restricted stock units described in the disclosure.

Was Celeste A. Clark’s PBH transaction an open-market buy or a compensation award?

The transaction was a compensation-related equity award, not an open-market purchase. Clark received 2,981 restricted stock units at a stated value of $155,000 under Prestige Consumer Healthcare’s director compensation program, with no cash price paid per unit by her.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 04:08 PM Accepted by SEC EDGAR 08/05/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clark Celeste A.

(Last) (First) (Middle)

660 WHITE PLAINS ROAD

(Street)

TARRYTOWN NEW YORK 10591

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Prestige Consumer Healthcare Inc. [ PBH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.01 per share	08/04/2026		A		2,981(1)	A	$0	16,511	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person received 2,981 restricted stock units equal to $155,000 divided by the closing stock price of $52.00 on August 4, 2026, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control.

	/s/ Celeste Clark by Christine Sacco Attorney-in-Fact pursuant to Power of Attorney dated May 4, 2021on file with the Commission	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)